1. Home
  2. MDWD vs ARAY Comparison

MDWD vs ARAY Comparison

Compare MDWD & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • ARAY
  • Stock Information
  • Founded
  • MDWD 2000
  • ARAY 1990
  • Country
  • MDWD Israel
  • ARAY United States
  • Employees
  • MDWD N/A
  • ARAY N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • ARAY Medical/Dental Instruments
  • Sector
  • MDWD Health Care
  • ARAY Health Care
  • Exchange
  • MDWD Nasdaq
  • ARAY Nasdaq
  • Market Cap
  • MDWD 184.8M
  • ARAY 180.0M
  • IPO Year
  • MDWD 2014
  • ARAY 2007
  • Fundamental
  • Price
  • MDWD $17.64
  • ARAY $2.24
  • Analyst Decision
  • MDWD Strong Buy
  • ARAY Strong Buy
  • Analyst Count
  • MDWD 1
  • ARAY 1
  • Target Price
  • MDWD $25.00
  • ARAY $9.00
  • AVG Volume (30 Days)
  • MDWD 68.1K
  • ARAY 669.1K
  • Earning Date
  • MDWD 11-26-2024
  • ARAY 01-29-2025
  • Dividend Yield
  • MDWD N/A
  • ARAY N/A
  • EPS Growth
  • MDWD N/A
  • ARAY N/A
  • EPS
  • MDWD N/A
  • ARAY N/A
  • Revenue
  • MDWD $19,720,000.00
  • ARAY $444,204,000.00
  • Revenue This Year
  • MDWD $10.37
  • ARAY $6.64
  • Revenue Next Year
  • MDWD $26.36
  • ARAY $5.69
  • P/E Ratio
  • MDWD N/A
  • ARAY N/A
  • Revenue Growth
  • MDWD N/A
  • ARAY N/A
  • 52 Week Low
  • MDWD $11.04
  • ARAY $1.40
  • 52 Week High
  • MDWD $24.00
  • ARAY $2.99
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 49.76
  • ARAY 60.03
  • Support Level
  • MDWD $15.80
  • ARAY $2.04
  • Resistance Level
  • MDWD $19.60
  • ARAY $2.34
  • Average True Range (ATR)
  • MDWD 0.98
  • ARAY 0.15
  • MACD
  • MDWD 0.06
  • ARAY 0.03
  • Stochastic Oscillator
  • MDWD 48.42
  • ARAY 82.76

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Share on Social Networks: